The National Pharmaceutical Pricing Authority (NPPA) published revised MRPs for 543 brands of anti-cancer medicines on 28 October 2026, effective 9 November 2026.
The list applies the 30% trade-margin cap notified on 17 October 2026 for 137 non-scheduled anti-cancer drugs under Paragraph 19 of the DPCO, 2013.
Some generic and biosimilar brands fell by over 90% — Palbopro (palbociclib) by 93% and Samtepa (thiotepa) by 91%.
High-priced patented brands such as Keytruda and Tagrisso were unchanged, because their margins already sat below the cap.
Parent law under which the Drugs (Prices Control) Order is issued
Lets the government fix or revise the price of any drug, including a non-scheduled one, in public interest — the power behind the 30% cap and these MRPs
Scheduled medicines, drawn from the National List of Essential Medicines (NLEM 2022: 384 medicines), carry ceiling prices; the 137 drugs here are outside it, where only a 10% annual MRP rise is normally monitored
Fixes and revises drug prices and enforces the DPCO; set up in 1997
Reserved orders on 27 October 2026 in a case on capping trade margins across non-scheduled drugs, after criticising the NPPA's enforcement
GS Paper 2 > Health; GS Paper 3 > Pharmaceutical sector regulation
General Awareness > Economy/Governance
The difference between the price to the stockist/retailer and the MRP; capped here at 30% of MRP
A medicine not in Schedule I of the DPCO (outside the NLEM), normally free-priced subject to a 10% annual rise limit
A biological medicine highly similar to an approved reference biologic